Hims & Hers Health (HIMS) Stock Soars 64% This Week After Novo Nordisk Partnership

TLDR

• Shares of HIMS are climbing 7% in premarket hours Thursday, building on Wednesday’s 10% advance for a fourth consecutive session of positive momentum
• This week’s 64% surge marks the strongest weekly performance in company history
• A strategic collaboration with Novo Nordisk enabled HIMS to offer FDA-cleared Ozempic and Wegovy through its digital platform, triggering the rally
• Barclays increased its target price from $25 to $29 while maintaining “overweight”; Bank of America moved from “underperform” to “neutral” with a $23 target
• Fourth-quarter earnings per share reached $0.08, significantly exceeding the $0.02 projection, while revenue of $617.8M came in marginally below the $619.5M forecast

Hims & Hers Health (HIMS) is experiencing an extraordinary week. Shares advanced approximately 7% during Thursday’s premarket session, extending Wednesday’s 10% rally. This marks the fourth consecutive trading day of positive momentum.

Hims & Hers Health, Inc., HIMS

By Wednesday’s market close, HIMS had climbed 64% for the week—the strongest weekly showing in the company’s trading history.

Monday initiated the rally when Hims & Hers announced that Novo Nordisk would distribute its weight-loss medications through the company’s platform. This partnership eliminated a significant legal uncertainty that had previously weighed on investor sentiment.

The arrangement permits Hims & Hers to offer FDA-authorized Ozempic and Wegovy directly to consumers via its telehealth platform. Market analysts view this development as a meaningful catalyst for both revenue expansion and profitability enhancement.

Midday Wednesday saw HIMS trading at $26.17, representing a $2.70 gain, while trading volume reached 51.6 million shares—substantially exceeding its typical 33.3 million average.

Analyst Upgrades Roll In

The collaboration with Novo Nordisk prompted multiple analyst revisions. Barclays elevated its price objective from $25 to $29 while retaining an “overweight” recommendation, suggesting approximately 10.8% potential appreciation from prevailing levels.

Bank of America shifted its stance from “underperform” to “neutral,” simultaneously raising its target from $12.50 to $23. Deutsche Bank adjusted its projection from $25 to $28 while maintaining a “hold” designation.

MarketBeat’s aggregated consensus stands at “Hold” with a price objective of $30.75. The analyst community breaks down as follows: three Buy ratings, thirteen Hold ratings, and one Sell rating.

Options market activity spiked notably, with approximately 322,000 call contracts changing hands—an indicator of significant bullish sentiment that can magnify upward price movements.

Q4 Earnings and Buyback

On February 23, HIMS disclosed its fourth-quarter financial results. Earnings per share of $0.08 substantially surpassed the $0.02 analyst consensus. Revenue totaled $617.8 million, narrowly missing the $619.5 million projection.

Despite the minor revenue shortfall, sales advanced 28.4% compared to the prior-year period. The company achieved a return on equity of 22.48% alongside a net margin of 5.47%.

The board authorized a $250 million share repurchase program, representing roughly 3% of outstanding shares. Such authorizations frequently indicate management confidence that shares are trading below intrinsic value.

Analysts project full-year earnings per share of $0.29 for the current fiscal period.

The stock’s 52-week trading range spans $13.74 to $70.43. Wednesday’s closing price positions shares comfortably above the 50-day moving average of $24.31, though still trailing the 200-day average of $37.75.

Notwithstanding this week’s impressive gains, short interest warrants monitoring. Analysts have identified potential squeeze dynamics as a volatility source—rallies fueled by short covering can reverse abruptly when speculative pressure subsides.

Institutional shareholders control 63.52% of HIMS stock. Company insiders maintain a 17.71% stake, though they divested 80,463 shares during the previous quarter.

The post Hims & Hers Health (HIMS) Stock Soars 64% This Week After Novo Nordisk Partnership appeared first on Blockonomi.